PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 158 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2018. The put-call ratio across all filers is 0.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $4,000 | 0.0% | 350 | 0.0% | 0.00% | – |
| Q2 2020 | $4,000 | +33.3% | 350 | 0.0% | 0.00% | – |
| Q1 2020 | $3,000 | -99.0% | 350 | -99.0% | 0.00% | -100.0% |
| Q4 2019 | $307,000 | +15250.0% | 35,140 | +25000.0% | 0.00% | – |
| Q3 2019 | $2,000 | 0.0% | 140 | 0.0% | 0.00% | – |
| Q2 2019 | $2,000 | -60.0% | 140 | 0.0% | 0.00% | – |
| Q1 2019 | $5,000 | +66.7% | 140 | 0.0% | 0.00% | – |
| Q4 2018 | $3,000 | -50.0% | 140 | 0.0% | 0.00% | – |
| Q3 2018 | $6,000 | -50.0% | 140 | -33.3% | 0.00% | – |
| Q2 2018 | $12,000 | +9.1% | 210 | +31.2% | 0.00% | – |
| Q1 2018 | $11,000 | -47.6% | 160 | -23.8% | 0.00% | – |
| Q4 2017 | $21,000 | -16.0% | 210 | 0.0% | 0.00% | – |
| Q3 2017 | $25,000 | +38.9% | 210 | 0.0% | 0.00% | – |
| Q2 2017 | $18,000 | +200.0% | 210 | +31.2% | 0.00% | – |
| Q1 2017 | $6,000 | -33.3% | 160 | -46.7% | 0.00% | – |
| Q4 2016 | $9,000 | 0.0% | 300 | 0.0% | 0.00% | – |
| Q1 2016 | $9,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 1,417,000 | $18,010,000 | 2.24% |
| Palo Alto Investors LP | 1,405,680 | $17,866,000 | 0.87% |
| PFM Health Sciences, LP | 2,838,376 | $36,076,000 | 0.68% |
| TANG CAPITAL MANAGEMENT LLC | 349,400 | $4,441,000 | 0.60% |
| Capital Impact Advisors, LLC | 127,029 | $1,615,000 | 0.59% |
| Leap Investments LP | 29,100 | $370,000 | 0.50% |
| Spark Investment Management LLC | 454,300 | $5,774,000 | 0.40% |
| Partner Investment Management, L.P. | 27,567 | $350,000 | 0.37% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 262,945 | $3,342,000 | 0.26% |
| Rock Springs Capital Management LP | 534,400 | $6,792,000 | 0.25% |